by Genova Sevice Department

On  March 6, Yan Xijun, chairman of the board of directors of Tasly holding group, and Wu naifeng, President of Tasly holding group,  went to Changzhou to visit Genova Biotech (Changzhou) Co., Ltd.  (hereinafter referred to as Genova Biotech), and exchanged views with  Genova Biotech on the strategic investment cooperation agreement signed  in 2017, creating a platform together and clarifying the direction of  scientific research, in order to deepen bilateral cooperation  We should promote the process of setting up diabetic chronic disease  management solutions, enrich the pipeline layout of innovative drugs,  and accelerate the construction of the large medical system.

On  December 5, 2017, Shanghai Tasly, a subsidiary of Tasly, signed  a strategic investment cooperation agreement with Genova Biotech, a  leading insulin development company in China, and invested US $50  million to support the international industrialization of Genova Biotech insulin.  This will enable the company to gain priority in selling products such  as glargine and other related products in Chinese mainland and add heavy  varieties in the field of diabetes.